SILVAN CONTRACTFLOW™
A division of Silvan Consulting Partners
Reducing Avoidable Delay in Clinical Site Activation
How transparent contract and budget operations improve execution today and site decisions tomorrow.
For emerging biopharma sponsors, clinical operations leaders, and CRO partners managing site contracts, budgets, and activation readiness.
Executive summary
The cost of an unclear startup record
Clinical study startup is often managed through email, spreadsheets, shared drives, status meetings, and separate sponsor and CRO trackers. Each tool can be useful, but the combined process leaves clinical operations leaders without a dependable view of where a site stands, why it is delayed, who owns the next action, and whether the contract and budget are truly ready for activation.
Avoidable operational drag
Contract language and site budgets move through repeated negotiation rounds. Issues wait between functions. Forecasts are built from status updates that may already be stale. Teams spend time reconstructing the history of a decision instead of moving the decision forward.
Material financial exposure
A 2024 peer-reviewed analysis estimated average direct operating costs of $23,737 per day for Phase II trials and $55,716 per day for Phase III trials — a clear reason to identify and actively manage the portion of delay you can control.
Central conclusion
A shared operational record can reduce avoidable delay by making contract status, budget progression, blockers, ownership, and target dates visible at the same time. The resulting history also gives sponsors better evidence for future country planning and site selection.
The problem
Why site startup loses time
Site activation depends on workstreams that do not always move at the same pace — regulatory and ethics review, contract negotiation, budget agreement, insurance, essential documents, clinical supplies, and internal approvals. Research on global randomized trials identifies contracts and budgets among the recurring categories that drive startup delay.
| Operational condition | What teams experience | Why it matters |
|---|---|---|
| Fragmented status | Different teams maintain different trackers, so leaders cannot tell which record is current. | Status meetings become reconciliation exercises. |
| Unclear ownership | A blocking issue is visible, but the next decision owner and due date are not. | Issues age between functions without escalation. |
| Contract and budget separation | Legal terms and financial terms advance in parallel but are reported independently. | A site may appear contract-ready while the budget remains unresolved. |
| Weak milestone discipline | Target and actual dates are captured inconsistently. | Forecasts rely on narrative updates rather than measured cycle time. |
| Lost negotiation history | Redlines, exceptions, and approval rationale remain in email threads. | Future teams repeat work and lose leverage from prior outcomes. |
The problem with status without context
A simple label such as "in negotiation" does not support a decision. Leaders need to know how long the item has remained in that state, the current budget delta, the unresolved clause or cost category, the responsible party, the next action, and the effect on the planned activation date. Without that context, escalation becomes reactive and portfolio reporting hides the work that is most likely to miss its target.
The economics
The economics of activation delay
A delay day can create several types of exposure. Direct trial operating costs continue while study teams, vendors, systems, and governance remain active. Enrollment capacity may arrive later than planned, and downstream milestones can shift.
Phase II
$23,737
Estimated direct operating cost per delay day
Phase III
$55,716
Estimated direct operating cost per delay day
Source: Smith, DiMasi and Getz, 2024. Estimates are study-level averages, not guaranteed savings.
A practical cost exposure model
A credible model isolates the portion of delay that improved contract and budget management could influence, rather than presenting full study-level cost as software savings:
Avoidable delay exposure = affected days × relevant daily operating cost × attributable share of the delay
For example, ten days of slippage during a Phase II program represents $237,370 in gross direct operating cost exposure. If only 20 percent of that delay was attributable to preventable contract and budget workflow issues, the relevant exposure is $47,474 — an illustration, not a promised return. Operational technology creates value through earlier detection, better prioritization, and shorter response time; it does not control ethics committees, institutional policy, investigator availability, or protocol amendments.
The solution
How transparent information flow reduces cost exposure
Transparent information flow means the people responsible for startup decisions work from the same current record. It requires more than a dashboard — each site record must connect status, dates, financial progression, documents, issues, owners, and actions.
Capture
Record each negotiation round, milestone, issue, and document.
Assign
Name the action owner and escalation path.
Prioritize
Surface overdue and at-risk work across the portfolio.
Learn
Compare cycle time and outcomes across sites and studies.
What changes operationally
- Clinical Contracts Managers focus on items that have exceeded target residence time instead of reviewing every agreement equally.
- Clinical Operations can see whether a planned activation date is supported by actual contract and budget progress.
- Budget exceptions route against defined parameters while Finance receives the final approved budget rather than owning the negotiation workflow.
- Leaders can distinguish a site-specific issue from a recurring institutional, country, template, or approval problem.
- CRO oversight discussions use common milestone data and documented actions instead of parallel narrative reports.
Control point
ContractFlow supports timely decisions only when teams update the record as part of the work. Data completeness, clear operating definitions, and agreed ownership remain management responsibilities.
Institutional memory
Turning startup data into better site decisions
The first benefit of structured startup data is execution visibility. The longer-term benefit is institutional memory. When sponsors standardize sponsor, program, study, country, institution, investigator, contract, and budget records, they can compare performance across future planning decisions — including how reliably an institution completes contracting and budget work.
| Structured measure | Question it answers | Decision supported |
|---|---|---|
| Median CTA cycle time | Which institutions routinely execute within target? | Site shortlisting and startup forecasts |
| Status residence time | Where does work wait longest? | Escalation design and resource allocation |
| Budget variance | Which sites or cost categories repeatedly exceed parameters? | Scenario planning and negotiation strategy |
| Negotiation rounds | Where is rework concentrated? | Template, playbook, and approval improvements |
| Activation readiness | How often do contract and budget completion align with planned activation? | Country and site portfolio planning |
| Issue history | Which institutions repeat the same legal or operational blockers? | Risk-adjusted site selection |
Better data does not replace feasibility. A fast contracting history does not prove a site can recruit the target population or produce high-quality data. Operational startup performance should be combined with patient access, therapeutic experience, investigator capacity, quality history, geography, diversity objectives, and protocol-specific feasibility. ContractFlow strengthens one evidence layer within that broader decision.
The platform
How SILVAN ContractFlow supports the operating model
ContractFlow organizes the contract and budget work that sits between site selection and activation, with distinct responsibilities for SILVAN administrators, Clinical Contracts Managers, and Clinical Operations users.
Dashboard and activation intelligence
Portfolio KPIs, overdue and at-risk items, average days open, status residence time, table and board views.
Clinical Trial Agreements
Terms status from drafting through execution, milestone dates, risks, action ownership, activity history, and document repository.
NDA and CDA management
Parallel tracking for confidentiality agreements, including priority, status, owners, blockers, and executed documents.
Site budget workstream
Negotiation rounds, financial progression, exceptions, approval decisions, parameters, and sponsor dependencies.
Site contracting view
Site-level summary across CTAs, NDAs, budgets, institutions, investigators, countries, and activation readiness.
Reference data
Standard sponsor, program, study, country, institution, and investigator entities that make comparisons reliable.
ContractFlow is not a replacement for a full CTMS, eTMF, regulatory information management system, or financial ERP. Its value comes from concentrating on the contract, budget, and activation decisions often diluted across those systems.
Implementation
Implementation priorities and measures
A useful implementation begins with operating definitions: when each status starts and ends, which milestone is authoritative, who owns each action type, when an issue becomes at risk, and what evidence closes the item.
Recommended first phase
- Configure sponsors, programs, studies, countries, institutions, and user roles.
- Define CTA, NDA and CDA, budget, and activation milestones with target cycle times.
- Import active records and the documents needed to support current decisions.
- Establish action ownership, escalation thresholds, and a weekly portfolio review.
- Measure baseline performance before setting improvement targets.
| Measure | Management use |
|---|---|
| Cycle time | Median days from initiation to first draft, site response, budget agreement, and execution. |
| Status aging | Number and percentage of records beyond target residence time. |
| Forecast reliability | Variance between planned and actual execution or activation dates. |
| Budget progression | Variance from sponsor initial to final approved budget and number of rounds. |
| Issue resolution | Median days to close blockers by type, owner, institution, and country. |
| Data discipline | Percentage of active records with current owner, next action, target date, and required documents. |
Conclusion
Manage the portion of startup delay you can control.
Site startup delay cannot be solved by a single system because many causes sit outside contract operations. Sponsors can, however, reduce the delay created by fragmented records, ambiguous ownership, late escalation, inconsistent milestone definitions, and missing negotiation history. SILVAN ContractFlow gives emerging biopharma and clinical operations teams a focused way to manage that controllable portion — protecting time, managing operating-cost exposure, and building a more realistic activation plan.
References
- Smith ZP, DiMasi JA, Getz KA. New Estimates on the Cost of a Delay Day in Drug Development. Therapeutic Innovation and Regulatory Science. 2024;58:855-862. doi.org/10.1007/s43441-024-00667-w
- Lai J, Forney L, Brinton DL, Simpson KN. Drivers of Start-Up Delays in Global Randomized Clinical Trials. Therapeutic Innovation and Regulatory Science. 2021;55:212-227. doi.org/10.1007/s43441-020-00207-2
- Hulstaert L, Twick I, Shtyrov Y, Verstraete H. Enhancing site selection strategies in clinical trial recruitment using real-world data modeling. PLOS ONE. 2024;19(3):e0300109. doi.org/10.1371/journal.pone.0300109
- SILVAN Consulting Partners. SILVAN ContractFlow Platform Guide. September 2026.
Cost estimates and operational outcomes vary by phase, therapeutic area, geography, protocol, portfolio, and sponsor operating model. ContractFlow is designed to improve visibility and workflow control. Actual time or cost reductions require appropriate implementation, complete data, timely user updates, and effective management action.